title: Decreased expression levels of PIWIL1, PIWIL2, and PIWIL4 are associated with worse survival in renal cell carcinoma patients.
abstract: Piwi-interacting RNAs (piRNAs) are a newly discovered class of small non-coding RNAs involved in silencing of transposable elements and in sequence-specific chromatin modifications. PIWI proteins (PIWIL), which belong to the family of Argonaute genes/proteins, bind to piRNAs and function mainly in germ line cells, but more recently were described to be functional also in stem cells and cancer cells. To date, there have been four PIWI proteins discovered in humans: PIWIL1, PIWIL2, PIWIL3, and PIWIL4. Recent studies suggested that deregulated expression of PIWI proteins and selected piRNAs is common to many types of cancers. We found significantly lower expression of PIWIL1 (P<0.0001) and piR-823 (P=0.0001) in tumor tissue in comparison to paired renal parenchyma. Further, we observed a progressive decrease in PIWIL1 (P=0.0228), PIWIL2 (P=0.0015), and PIWIL4 (P=0.0028) expression levels together with increasing clinical stage. PIWIL2 (P=0.0073) and PIWIL4 (P=0.0001) expression also progressively decreased with increasing Fuhrman grade. Most importantly, low-expression levels of PIWIL1 (P=0.009), PIWIL2 (P<0.0001), and PIWIL4 (P=0.0065) were significantly associated with worse overall survival in renal cell carcinoma (RCC) patients. Our results suggest the involvement of PIWIL genes and piR-823 in RCC pathogenesis, and indicate PIWIL1, PIWIL2, and PIWIL4 as potential prognostic biomarkers in patients with RCC.
authors.affiliation: Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
authors.forename: Robert
authors.initials: R
authors.lastname: Iliev
authors.affiliation: Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: Michal
authors.initials: M
authors.lastname: Stanik
authors.affiliation: Department of Urology, University Hospital Brno, Masaryk University Brno, Brno, Czech Republic.
authors.forename: Michal
authors.initials: M
authors.lastname: Fedorko
authors.affiliation: Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: Alexandr
authors.initials: A
authors.lastname: Poprach
authors.affiliation: Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
authors.forename: Petra
authors.initials: P
authors.lastname: Vychytilova-Faltejskova
authors.affiliation: Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
authors.forename: Katerina
authors.initials: K
authors.lastname: Slaba
authors.affiliation: Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: Marek
authors.initials: M
authors.lastname: Svoboda
authors.affiliation: Department of Diagnostic and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: Pavel
authors.initials: P
authors.lastname: Fabian
authors.affiliation: Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: Dalibor
authors.initials: D
authors.lastname: Pacik
authors.affiliation: Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
authors.forename: Jan
authors.initials: J
authors.lastname: Dolezel
authors.affiliation: Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Urology, University Hospital Brno, Masaryk University Brno, Brno, Czech Republic.
authors.forename: Ondrej
authors.initials: O
authors.lastname: Slaby
keywords: PIWIL; kidney cancer; piRNA
references.citation: Asian Pac J Cancer Prev. 2014;15(18):7553-8
references.pmid: 25292027
references.citation: Clin Transl Oncol. 2013 Jul;15(7):563-8
references.pmid: 23229900
references.citation: Acta Biochim Biophys Sin (Shanghai). 2015 May;47(5):315-24
references.pmid: 25854579
references.citation: Science. 2011 May 13;332(6031):848-52
references.pmid: 21566194
references.citation: RNA. 2009 Feb;15(2):337-45
references.pmid: 19144913
references.citation: EMBO J. 2008 Oct 22;27(20):2702-11
references.pmid: 18833190
references.citation: Science. 2007 Mar 16;315(5818):1587-90
references.pmid: 17322028
references.citation: Leukemia. 2015 Jan;29(1):196-206
references.pmid: 24732595
references.citation: Int J Clin Exp Pathol. 2012;5(4):315-25
references.pmid: 22670175
references.citation: Brain Res. 2011 Feb 10;1373:183-8
references.pmid: 21138738
references.citation: Genomics. 2003 Sep;82(3):323-30
references.pmid: 12906857
references.citation: BMC Cancer. 2012 Jun 29;12:272
references.pmid: 22748119
references.citation: Cancer Lett. 2015 Jan 28;356(2 Pt B):561-7
references.pmid: 25305452
references.citation: Mol Med. 2015 May 13;21:371-80
references.pmid: 25998509
references.citation: Int J Oncol. 2014 Dec;45(6):2385-92
references.pmid: 25269862
references.citation: Epigenetics. 2014 Jan;9(1):113-8
references.pmid: 24247010
references.citation: Oncotarget. 2015 Oct 13;6(31):31544-56
references.pmid: 25742785
references.citation: Biochim Biophys Acta. 2014 May;1842(5):686-90
references.pmid: 24509249
references.citation: Curr Biol. 2007 Jul 17;17(14):1265-72
references.pmid: 17604629
references.citation: Arch Virol. 2010 May;155(5):657-63
references.pmid: 20229117
references.citation: Database (Oxford). 2014 Nov 25;2014:bau110
references.pmid: 25425034
references.citation: Cancer Lett. 2012 Feb 1;315(1):12-7
references.pmid: 22047710
references.citation: Cancer. 2012 May 15;118(10):2708-17
references.pmid: 21989785
references.citation: Chin Med J (Engl). 2011 Jul;124(14):2144-9
references.pmid: 21933617